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Pituitary tumor development involves clonal expansion stimulated
by hormones and growth factorsycytokines. Using mRNA differ-
ential display, we found that the bone morphogenetic protein
(BMP) inhibitor noggin is down-regulated in prolactinomas from
dopamine D2-receptor-deficient mice. BMP-4 is overexpressed in
prolactinomas taken from dopamine D2-receptor-deficient female
mice, but expression of the highly homologous BMP-2 does not
differ in normal pituitary tissue and prolactinomas. BMP-4 is
overexpressed in other prolactinoma models, including estradiol-
induced rat prolactinomas and human prolactinomas, compared
with normal tissue and other pituitary adenoma types (Western
blot analysis of 48 tumors). BMP-4 stimulates, and noggin blocks,
cell proliferation and the expression of c-Myc in human prolacti-
nomas, whereas BMP-4 has no action in other human pituitary
tumors. GH3 cells stably transfected with a dominant negative of
Smad4 (Smad4dn; a BMP signal cotransducer) or noggin have
reduced tumorigenicity in nude mice. Tumor growth recovered in
vivo when the Smad4dn expression was lost, proving that BMP-
4ySmad4 are involved in tumor development in vivo. BMP-4 and
estrogens act through overlapping intracellular signaling mecha-
nisms on GH3 cell proliferation and c-myc expression: they had
additive effects at low concentrations but not at saturating doses,
and their action was inhibited by blocking either pathway with the
reciprocal antagonist (i.e., BMP-4 with ICI 182780 or 17b-estradiol
with Smad4dn). Furthermore, coimmunoprecipitation studies dem-
onstrate that under BMP-4 stimulation Smad4 and Smad1 physi-
cally interact with the estrogen receptor. This previously unde-
scribed prolactinoma pathogenesis mechanism may participate in
tumorigenicity in other cells where estrogens and the type b
transforming growth factor family have important roles.
signal transduction u pituitary neoplasms
There is little doubt that estrogens and growth factors areinvolved in the control of lactotroph cell proliferation. In
vitro, as well as clinical, evidence demonstrates the tumorigenic
action of estrogen in prolactinomas. Thus, the number of lac-
totroph cells increases during pregnancy (1). Prolactinomas
occur more frequently in women and increase in size during
pregnancy or estrogen treatment (2, 3), and, at least in human
prolactinomas, estrogen receptor (ER) expression is positively
related to size (4). Dominant-negative ER inhibits growth of
lactotroph cells in nude mice (5). In female rats, estrogens
promote the development of experimental prolactinomas (6, 7),
whereas in dopamine D2-receptor (D2R)-deficient mice
(D2R2/2), a new animal model for prolactinomas, these grow
spontaneously only in females (8, 9). Estrogens regulate soma-
tostatin receptor expression in prolactin (PRL)-secreting pitu-
itary tumor cells (10). By using GH3 rat tumor cells and other
models, it has been shown that estrogen-induced pituitary
tumor-derived transforming gene (PTTG) and fibroblast growth
factor are involved in prolactinoma pathogenesis (7).
Pituitary cells produce cytokines and express their receptors.
This constitutes the basis for the paracrine and autocrine action of
cytokines in the control of hormone production and cell prolifer-
ation in the pituitary (11–15). Growth factors and hypothalamic
factors also play a part in the molecular and cellular mechanisms
that lead to prolactinoma development (11–13). Bone morphoge-
netic proteins (BMPs), as well as other members of the type b
transforming growth factor (TGFb) family, transduce signals
through Smad4, a signal cotransducer (16–18). Smad4, in turn,
regulates c-myc, a protooncogene that controls cell cycle and
mediates the effects of TGFb on cell proliferation (19, 20). We
report here a previously undescribed mechanism for prolactinoma
growth that involves BMP-4, Smad4, and estrogens.
Methods
Animal Housing and Experiments. Animals were housed under
standard conditions. Anterior pituitaries from female D2R2y2,
heterozygous (D2R1/2), and C57 normal control (D2R1/1) mice
were used (8, 9). Primary prolactinomas were induced in Spra-
gue–Dawley female rats by weekly i.m. injections of 40 mg of
17b-estradiol, carried out for 4 weeks as described (21). N:NIH
(S)-nu nude mice were injected s.c. with 13 106 cells, and tumor
growth was determined as described (22). All protocols were
approved by the Ethical Committee on Animal Care and Use,
University of Buenos Aires, Argentina.
Differential Display. A pituitary tumor from an 18-month-old
female D2R2/2 was used for differential display (8, 9). Normal
pituitary tissue from D2R1/1 was used for comparison. Total
RNA was isolated as described (23). mRNA differential
display was performed with an RNAimage kit (Gene Hunter,
Nashville, TN).
PCR. Total RNA was extracted from a pituitary tumor from a female
D2R2/2 and from pituitaries from D2R1/2 and D2R1/1 as described
(23). RT-PCR was performed under restrictive conditions by using
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only 25 amplification cycles (1 min, 94°C; 1 min, 55°C; 1 min, 72°C)
to obtain band intensities proportional to the RNA amount (24).
Actin was amplified from the same samples under the same
conditions, as an internal control. The primer sequences were:
noggin, CGGGGACGCGGGACGAAGAG, CGGTCCTCT-
GGGGGCGAAGT; actin, ACGGGGTCACCCACACTGTGC,
CTAGAAGCATTTGCGGTGGACGATG.
Plasmids. The Smad4 dominant negative (Smad4dn) expression
vector consists of a truncated DPC4 (Smad4) cDNA (1–514)
fused to FLAG expressed under the control of the cytomega-
lovirus (CMV) promoter (25). The noggin expression vector
contains 1 kb of the mouse noggin cDNA driven by the trans-
lation elongation factor (EF)-1a promoter (26).
Cell Culture and Stable Clones. All materials were from Invitrogen
unless otherwise stated. GH3 cells were cultured in DMEM with
10% FCS as described (27). Treatments with 17b-estradiol were
performed in phenol red-free DMEM with stripped FCS (28).
GH3 cells were stably transfected with noggin or Smad4dn
expression vectors using Lipofectamine and selected with 600
ngyml G418. GH3–noggin clones were tested for noggin expres-
sion by Northern blot analysis (26). GH3–Smad4dn clones were
checked by Western blot analysis with anti-FLAG antibodies
(Chemicon). Three additional stable clones for each construct
had results similar to the one shown. Cells were treated with 10,
50, 100, or 200 ngyml BMP-4; 0.1 or 1 mgyml noggin (both from
R & D Systems); 1, 10, or 100 nM 17b-estradiol; 1 mM tamoxifen
(both from Sigma); 10 ngyml platelet-derived growth factor
(PDGF; Roche Molecular Biochemicals); 10 or 100 nM thyro-
tropin-releasing hormone (TRH; Bachem); or 1, 10, or 100 nM
or 1 mM ICI 182780 (Tocris Cookson, Ballwin, MO).
Tumors. Pituitary tumors were obtained from patients with
hyperprolactinemia, acromegaly, Cushing’s disease, or clinical
diagnosis of nonfunctioning pituitary adenomas. Hormone pro-
duction was confirmed by immunohistochemistry, and tumor
samples were treated as explants, as described (23, 29).
Cell Proliferation and PRL Measurement. A WST-1 assay (Roche
Molecular Biochemicals) was used to measure cell proliferation
as described (30). Staining with acridine orange and ethidium
bromide was used to rule out toxic effects. Rat PRL was
measured by RIA as described (27).
Coimmunoprecipitation. GH3 cells were treated as described for
1 h, and then cell lysates were immunoprecipitated with anti-
Smad4, anti-ERa, or anti-ERb. Protein A Sepharose (Amer-
sham Pharmacia Biotech) was used as described (31). Experi-
ments were performed by using agarose-conjugated anti-Smad4
(Santa Cruz Biotechnology) with similar results.
Western Blot Analysis. Cells were treated as described; lysates were
analyzed by PAGE and blotted by using standard procedures,
and anti-BMP-4, anti-Smad1, anti-Smad2, anti-Smad4, anti-
ERa, anti-ERb, anti-c-Myc (Santa Cruz Biotechnology), or
anti-FLAG (Chemicon) was used. Anti-b-actin (Sigma) was used
routinely as loading control.
Statistical Analysis. Results are expressed as mean 6 SE. Differ-
ences were assessed by one-way ANOVA in combination with
Scheffe´’s test.
Results
Overexpression of BMP-4 in Prolactinomas. We used mRNA differ-
ential display in female D2R2/2 mice to compare the gene
expression pattern in normal anterior pituitaries and prolacti-
nomas. A band present only in the normal pituitary tissue was
identified as noggin, a specific inhibitor of BMP action that does
not inhibit other members of the TGFb family (16, 32) (Fig. 1a).
Comparative RT-PCR confirmed the differential expression of
Fig. 1. Differential expression of the BMP-4 system in prolactinomas. (a)
mRNA differential display of pituitaries from D2R1/1 (control) mice and
D2R2/2 mice with prolactinoma. Arrow indicates the band identified as nog-
gin. These results represent four independent amplifications. (b) Comparative
RT-PCR was performed to detect noggin, BMP-2, and BMP-4 in RNA extracted
from pituitaries taken from D2R1/1, D2R1/2, or D2R2/2 mice. Actin amplifica-
tion was performed in the same reaction tubes under suboptimal conditions
as an internal standard. These results represent three independent RT-PCR
reactions. (c) Differential expression of BMP-4 protein was confirmed by
Western blot analysis in protein extracts from normal pituitaries taken from
D2R1/1 (control) mice and from D2R1/2 mice without tumors, and from pro-
lactinomas taken from D2R2/2 mice. Equal loading was assessed by b-actin
detection. These results represent two independent experiments with similar
results. (d) BMP-4 was measured by Western blot analysis in pituitaries from
four female Sprague–Dawley rats treated with vehicle (control; plasma PRL,
38.656 0.45 ngyml) or 200 mgyml 17b-estradiol (E2; plasma PRL, 446.56 42.5
ngyml) as detailed in Methods. Equal loading was assessed by b-actin detec-
tion. (e) BMP-4 was examined by Western blot analysis in 51 protein homog-
enates, each obtained from one of 51 individual samples (distributed as shown
in f ) from normal human pituitary tissue (NP; n 5 3); human prolactinomas
(PRL; n 5 12); human corticotropin (ACTH)-secreting tumors (ACTH; n 5 11);
human growth hormone (GH)-secreting tumors (GH; n 5 12); or clinically
inactive pituitary tumors (NF; n513); one representative example of each case
is shown. Equal loading was assessed by b-actin detection. ( f) BMP-4 detec-
tions by Western blot from the 51 samples used in e were analyzed by
densitometry and normalized by using b-actin values as loading control. F,
normal human pituitary tissue; h, human prolactinomas; E, human ACTH-
secreting tumors;L, human GH-secreting tumors; ‚, clinically inactive pitu-
itary tumors. In many cases, symbols corresponding to individual tumors
overlap. BMP-4 levels in human prolactinomas are significantly different (P,
0.01) with respect to all other groups, which show no statistical difference
among them (ANOVA with Scheffe´’s test).
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noggin (Fig. 1b). BMP-4 was overexpressed in prolactinomas
taken from female D2R2/2 mice (Fig. 1 b and c). Expression
levels of the highly homologous BMP-2, however, did not differ
between normal pituitary tissue and prolactinomas (Fig. 1b). An
equivalent overexpression of BMP-4 also was found in prolacti-
nomas from female Sprague–Dawley rats, induced by 17b-
estradiol treatment (Fig. 1d). Given our finding of BMP-4
overexpression in different models of pituitary prolactinomas,
we next assessed BMP-4 expression in 48 human pituitary
tumors. BMP-4 also was significantly overexpressed in human
prolactinomas, compared with normal human pituitaries and
other pituitary adenoma types (Fig. 1 e and f ). The protein
expression of Smad4 was detected in all models of prolactino-
mas, i.e., D2R2/2 mice, 17b-estradiol-treated rats, and human
prolactinomas (data not shown).
BMP-4 Stimulates Prolactinoma Development. BMP-4 did not sig-
nificantly affect PRL production in GH3 and in normal rat
pituitary cells (data not shown). BMP-4 did lead to a major
increase in cell proliferation in GH3 cells; this effect was blocked
by noggin (Fig. 2a). We next tested the ability of BMP-4 to
stimulate in human tumors the expression of c-Myc (Fig. 2b), an
important regulator of cell cycle progression and a target for
Smad pathways (19, 20). In human pituitary prolactinoma ex-
plants, but not in other human adenoma types, BMP-4 stimu-
lated and noggin inhibited (as they did in GH3 proliferation)
c-Myc expression (Fig. 2b).
To further study tumor formation in nude mice, we produced
GH3 clones stably transfected with a Smad4dn (GH3–
Smad4dn). Smad4dn blocked the stimulatory effect of BMP-4 on
cell proliferation (Fig. 2c). However, the action of PDGF (which
is not mediated by Smad4) was not affected (Fig. 2c). Similar
results were obtained with clones overexpressing noggin (data
not shown).
Tumor formation in nude mice with GH3 cells expressing
Smad4dn was reduced markedly, demonstrating that the BMP-4
stimulatory pathway plays a role in the development of pituitary
tumors in vivo. Cells transfected with an empty vector formed
fast-growing, large tumors and had high c-Myc levels, whereas
Smad4dn dramatically reduced tumor growth and c-Myc expres-
sion (Fig. 3). Similar results were obtained with cells transfected
with a noggin expression vector (data not shown). Two tumors
produced by Smad4dn cells escaped from the initial Smad4dn
inhibition and showed a late increase in tumor size similar to that
shown by cells transfected with an empty vector. The molecular
analysis of these tumors showed that both had lost in vivo the
expression of Smad4dn and had recovered c-Myc expression at
levels similar to those of the controls (Fig. 3c), providing direct
evidence of the involvement of BMP-4 and Smad4 in tumori-
genesis in vivo.
Crosstalk Between BMP-4 and Estrogen Signaling. We next studied
whether a crosstalk exists between BMP-4 and estrogen signal-
ing. BMP-4 and 17b-estradiol individually increased GH3 cell
proliferation; both treatments in combination did not lead to any
further increase at saturating doses, but had an additive effect at
low concentrations (Fig. 4a). Blocking either pathway (i.e.,
estrogens or BMP-4) with the reciprocal antagonist (i.e., BMP-4
with ICI 182780 or 17b-estradiol with Smad4dn) resulted in a
partial but significant inhibition of its action on cell proliferation
(Fig. 4 b and c), confirming that BMP-4 and estrogens act
through overlapping intracellular signaling mechanisms. The
interaction between BMP-4 and 17b-estradiol was evidenced
further by a similar expression pattern of the estrogen and Smad4
target c-Myc (19, 20, 33) (Fig. 4d).
Coimmunoprecipitation studies demonstrate that the ER can
physically interact with Smad4 and the specific BMP signal
transducer, Smad1. Thus, Smad4 and Smad1, but not Smad2,
Fig. 2. BMP-4 stimulates the proliferation of a lactotroph tumor cell line. (a)
GH3 cells were treated with BMP-4, noggin (Nog), or their combination for
72 h. Cell proliferation was measured by WST-1 assay. Results represent the
mean6 SE of quadruplicates from four independent experiments. *, P, 0.01
with respect to basal values; Œ, P , 0.01 with respect to 200 ngyml BMP-4
stimulation (ANOVA with Scheffe´’s test). (b) Tumor explants were treated
with BMP-4 or noggin (Nog) for 90 min, and c-Myc expression was analyzed by
Western blot analysis as a parameter related to cell proliferation in different
types of pituitary tumors (n 5 9). PRL, human prolactinoma; GH, human
GH-secreting pituitary tumor; NF, clinically inactive pituitary tumor. Equal
loading was assessed by b-actin detection. (c) Cell proliferation under BMP-4
treatment was compared between GH3 cells stably transfected with an empty
vector and GH3 cells with Smad4dn. Cells were treated for 72 h, and prolif-
eration was measured by WST-1 assay. PDGF stimulation of GH3 cell prolifer-
ation was used as a positive control unrelated to BMP signaling. Bars represent
the mean6 SE of the differences between the treated and the corresponding
basal values of quadruplicates from three independent experiments. *, P ,
0.01 with respect to the corresponding basal values (GH3–vector, 0.305 6
0.015; GH3–Smad4dn, 0.3656 0.020); Œ, P, 0.01 comparing GH3–vector and
GH3–Smad4dn cells under the same treatment (ANOVA with Scheffe´’s test).
(Inset) Smad4dn (FLAG) expression was checked by Western blot analysis
against a FLAG epitope contained in the GH3 cells with Smad4dn, as described
in Methods.
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coimmunoprecipitated with ERa in the presence of BMP-4,
whereas, under TGFb treatment, Smad2 and Smad4, but not
Smad1, coimmunoprecipitated with ERa (Fig. 5). Control an-
tibodies did not produce coimmunoprecipitated proteins (Fig. 5
Fig. 4. Crosstalk between BMP-4 and estrogen signaling. (a) GH3 cells
were treated with BMP-4, 17b-estradiol (E2), or their combination as indicated.
After 72 h, cell proliferation was measured by WST-1 assay. As a control, cells
were treated with TRH in combination with BMP-4, which, at the same saturating
dose at which it did not interact with estrogen, produced a greater effect than
did BMP-4 or TRH individually. *, P,0.01 compared with basal values;Œ, P,0.01
compared with 10 ngyml BMP-4 or 1 nM 17b-estradiol individually; ■ , P ,
0.01compared with TRH or 200 ngyml BMP-4 individually (ANOVA with Scheffe´’s
test). (b) GH3 cells were treated with BMP-4, ICI 182780 (ICI), or their combination
as indicated. After 72 h, cell proliferation was measured by WST-1 assay.
The effect of TRH (used as a control) was not inhibited, indicating the specificity
of the effect of ICI 182780. Similar results were obtained with tamoxifen. Bars
representthemean6SEofquadruplicates fromthree independentexperiments.
*, P , 0.01compared with basal values; Œ, P , 0.01 compared with 200 ngyml
BMP-4 (ANOVA with Scheffe´’s test). (c) 17b-estradiol stimulation of cell prolifer-
ation was compared between GH3–vector and GH3–Smad4dn cells. Cells were
treated with 17b-estradiol for 72 h, and cell proliferation was measured by WST-1
assay. PDGF stimulation was performed as a positive control of similar respon-
siveness between cell lines. Bars represent the mean 6 SE of the differences
between the treated and the corresponding basal values of quadruplicates from
three independent experiments. *, P , 0.01 compared with the corresponding
basal values (GH3–vector, 0.3356 0.011; GH3–Smad4dn, 0.3956 0.020); Œ, P,
0.01 between the two cell lines under the same treatment (ANOVA with Scheffe´’s
test). (d) GH3 cells were treated with BMP-4, 17b-estradiol, ICI 182780, or their
combination as indicated. After a 1-h treatment, cells were lysed, and the protein
extracts were analyzed by Western blot for c-Myc as described in Methods. Equal
loading was assessed by b-actin detection. One representative of three indepen-
dent experiments with similar results is shown.
Fig. 3. Smad4dn inhibits tumor growth in vivo. (a) Nude mice were injected
s.c. with GH3 cells stably transfected with an empty vector (GH3–vector) or
with a vector expressing Smad4dn (GH3–Smad4dn). At 30 days after injection,
large tumors formed by GH3–vector cells were observed and compared with
the smaller tumors in animals injected with GH3–Smad4dn cells. (b) Tumors of
animals injected as indicated in a were detected 15 days after injection, and
growth was monitored for a total of 30 days. l, GH3–vector; E, GH3–
Smad4dn. These results represent two independent experiments in which
three and four animals, respectively, were injected with each cell line. (c) c-Myc
and Smad4dn (FLAG) expression was analyzed by Western blot in tumor
samples from nude mice injected with GH3 cells stably transfected with an
empty vector (control tumor growth) or Smad4dn-expressing GH3 cells (in-
hibited tumor growth) after 30 days. Two additional tumor samples that
escaped from the initial Smad4dn inhibition and presented a late increase in
tumor size (late tumor growth) were analyzed for c-Myc and Smad4dn (FLAG)
expression by Western blot. Equal loading was assessed by b-actin detection.
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e and f ). Similar results were obtained with ERb (data not
shown).
Discussion
In this report we show that noggin is down-regulated in D2R2/2
mouse prolactinomas and BMP-4 is overexpressed in this and
other prolactinoma models, including estradiol-induced rat pro-
lactinomas and human pituitary adenomas, compared with
normal tissue and other pituitary adenoma types. In addition,
BMP-4 has a strong stimulatory effect on cell proliferation. This
system is active both in vitro and in vivo as demonstrated by the
inhibition of tumor growth in nude mice by Smad4dn or noggin
overexpression. Other members of the TGFb family have inhib-
itory effects on prolactinomas (34, 35), and TGFb inhibits c-Myc
expression (19, 36). However, BMP-4 positive growth signaling
in the control of PRL-secreting cells overrides the negative effect
of TGFb, because GH3–Smad4dn cells (which do not respond to
either BMP-4 or TGFb) have a blunted growth in nude mice.
Both noggin, which is specific for BMP-4, and Smad4dn blocked
tumor growth in vivo. Because BMP-4 stimulates prolactinoma
growth, whereas TGFb inhibits it, the results obtained with
Smad4dn clones provide even stronger confirmation of the role
of BMP-4 in tumor growth. One of the central questions in tumor
growth control is how tumor cells escape from the inhibition of
cell proliferation by TGFb family members (37). We propose
that prolactinomas, in which BMP-4 stimulates cell proliferation,
may be an interesting model to investigate these mechanisms.
BMP-2 and BMP-4 have been shown to play a role in the initial
steps of the development of the anterior pituitary (38). For
instance, BMP-4 is required for the proliferation of the Rathke’s
pouch placode, which gives rise to PRL-secreting cells, among
others. The overexpression of noggin or a dominant-negative
BMP-receptor (BMPR1A) in the anterior pituitary leads to an
arrest in the development of PRL-secreting cells (38). This fits
in with our results, which introduce the concept of BMP-4 as a
positive stimulus for the proliferation of adult PRL-secreting
tumor cells.
Our data show that the BMP-4 signal transduction interacts
with estrogen and that this interaction is mediated by ERs and
Smad4. This interaction may explain the high incidence of
prolactinomas in women. BMP-4 effects are partially mediated
by ERs, and, conversely, estradiol effects are partially mediated
by Smad4, because antiestrogens and Smad4dn partially inhibit
the effects of BMP-4 and estradiol, respectively. The fact that
antiestrogens partially inhibit BMP-4 effects in prolactinoma
cells suggests that the crosstalk between BMP-4 and estrogens
could provide a new target for specific antiestrogenic drugs.
Moreover, the physical interaction between Smad4 and ER may
be present not only in prolactinoma cells but also in others such
as breast and bone, in which both estrogens and the TGFb family
play important roles (16, 37, 39).
Previous studies on the signal transduction of TGFb family
members have shown that Smad4 is a common mediator that
binds to DNA and regulates gene transcription (40). Smads may
interact with other transcription partners (41), and some of the
factors that cooperate with Smad to regulate gene transcription
have been identified (16, 37, 40). The transcriptional mecha-
nisms of estrogen action have been characterized (42), and
interactions between different ERs (a and b) with different
ligands, response elements, and nuclear cofactors may explain
the tissue specificity of estrogen and antiestrogen effects (42, 43).
Smad proteins mediate transcriptional activation or repression
depending on their associated partners (44). Here we describe a
direct physical interaction between ER, Smad4, and Smad1 (but
not Smad2) in association with a specific BMP-4-induced
crosstalk mechanism that stimulates cell proliferation. In con-
Fig. 5. Smad and ER physical association. GH3 cells were treated with BMP-4, 17b-estradiol (E2), or TGFb for 1 h. Cell lysates were immunoprecipitated with
Protein A Sepharose in combination with the following primary antibodies: (a and e) anti-Smad4, (b–d) anti-ERa, and ( f) anti-c-Myc. The immunoprecipitated
fractions and the whole lysates were analyzed by Western blot as described in Methods, by using the following antibodies: (a) anti-ERa, (b and f ) anti-Smad4,
(c) anti-Smad1, (d) anti-Smad2, and (e) anti-c-Myc, which was used as an unrelated control. One representative of four independent experiments with similar
results is shown. Similar results were obtained by using anti-Smad4 conjugated with agarose.
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trast, TGFb induced a physical interaction between ER and
Smad2 or Smad4, but not Smad1. A similar interaction between
ER and TGFb-induced Smad3 recently has been shown in a
reconstituted signaling system (45). These different signaling
complexes and associated proteins specifically induced by
BMP-4 or TGFb might provide a basis to explain their different
proliferative effects. The rapid induction of c-myc by BMP-4 and
estrogens suggest that the c-myc promoter might be a direct
target of these ER–Smad complexes. BMP-4, other members of
the TGFb family, and estrogens play significant roles in several
tumor types and in bone physiology. We demonstrate for the first
time that a BMP-4–Smad–ER molecular regulatory mechanism
exists and is of critical importance in a physiologically relevant
model. Similar mechanisms may well play a part in the progres-
sion of other diseases.
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